Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA227391
Max Phase: Preclinical
Molecular Formula: C15H10ClNO3
Molecular Weight: 287.70
Molecule Type: Small molecule
Associated Items:
ID: ALA227391
Max Phase: Preclinical
Molecular Formula: C15H10ClNO3
Molecular Weight: 287.70
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(/C=C/c1ccc([N+](=O)[O-])cc1)c1ccc(Cl)cc1
Standard InChI: InChI=1S/C15H10ClNO3/c16-13-6-4-12(5-7-13)15(18)10-3-11-1-8-14(9-2-11)17(19)20/h1-10H/b10-3+
Standard InChI Key: JBXAGWCLKWPVFB-XCVCLJGOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 287.70 | Molecular Weight (Monoisotopic): 287.0349 | AlogP: 4.14 | #Rotatable Bonds: 4 |
Polar Surface Area: 60.21 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.43 | CX LogD: 4.43 |
Aromatic Rings: 2 | Heavy Atoms: 20 | QED Weighted: 0.37 | Np Likeness Score: -0.89 |
1. Batovska D, Parushev S, Slavova A, Bankova V, Tsvetkova I, Ninova M, Najdenski H.. (2007) Study on the substituents' effects of a series of synthetic chalcones against the yeast Candida albicans., 42 (1): [PMID:17007965] [10.1016/j.ejmech.2006.08.012] |
2. Lahtchev KL, Batovska DI, Parushev SP, Ubiyvovk VM, Sibirny AA.. (2008) Antifungal activity of chalcones: a mechanistic study using various yeast strains., 43 (10): [PMID:18280009] [10.1016/j.ejmech.2007.12.027] |
3. Batovska D, Parushev S, Stamboliyska B, Tsvetkova I, Ninova M, Najdenski H.. (2009) Examination of growth inhibitory properties of synthetic chalcones for which antibacterial activity was predicted., 44 (5): [PMID:18584918] [10.1016/j.ejmech.2008.05.010] |
4. Wani MY, Bhat AR, Azam A, Lee DH, Choi I, Athar F.. (2012) Synthesis and in vitro evaluation of novel tetrazole embedded 1,3,5-trisubstituted pyrazoline derivatives as Entamoeba histolytica growth inhibitors., 54 [PMID:22658085] [10.1016/j.ejmech.2012.03.049] |
5. Manzoor S, Hoda N.. (2020) A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review., 206 [PMID:32942081] [10.1016/j.ejmech.2020.112787] |
Source(1):